Business ❯ Healthcare ❯ Pharmaceuticals

Acquisitions

Vaccine Development Biogen Novo Nordisk Johnson & Johnson AstraZeneca Melinta Therapeutics Sanofi Metsera Gilead Sciences Jazz Pharmaceuticals Pfizer Digital Pathology Merck and Cidara Acquisition Alkermes Novartis-Avidity Acquisition Sanofi-Dren Bio Agreement Merck Eris Lifesciences Mergers and Acquisitions Eli Lilly & Co. Organon-Dermavant Merck KGaA Cipla Edgewise Therapeutics Eli Lilly and Verve Therapeutics GSK Acquisition of RAPT Therapeutics Sanofi and Dynavax Ophthalmology Eli Lilly Neurocrine Biosciences US WorldMeds

11 ARTICLES

2w ago

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

The all-cash $77-per-share tender offer is intended to add FB102, a first-in-class anti-CD122 antibody, to broaden argenx’s immunology pipeline beyond Vyvgart.

4 ARTICLES

2mo ago

Servier to Buy Edgewise Muscular Dystrophy Unit for Up to $2.65 Billion

6 ARTICLES

3mo ago

Roche to Acquire PathAI for $750 Million Upfront Plus Up to $300 Million in Milestones

18 ARTICLES

4mo ago

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

18 ARTICLES

4mo ago

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

4 ARTICLES

6mo ago

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

11 ARTICLES

6mo ago

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

8 ARTICLES

9mo ago

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

11 ARTICLES

9mo ago

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

4 ARTICLES

9mo ago

CorMedix Shares Jump After Q3 Beat as Company Lifts 2025 Outlook

4 ARTICLES

9mo ago

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

14 ARTICLES

10mo ago

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

7 ARTICLES

10mo ago

DoorDash Signs Multi-Year Deal to Use Serve Robotics’ Sidewalk Bots for Deliveries

3 ARTICLES

last yr.

Adaptimmune Sells Tecelra and Late-Stage Cell Therapies to U.S. WorldMeds for $55M

9 ARTICLES

last yr.

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

9 ARTICLES

last yr.

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Acquisitions

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

Servier to Buy Edgewise Muscular Dystrophy Unit for Up to $2.65 Billion

Roche to Acquire PathAI for $750 Million Upfront Plus Up to $300 Million in Milestones

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

CorMedix Shares Jump After Q3 Beat as Company Lifts 2025 Outlook

Never miss stories about

Acquisitions

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

DoorDash Signs Multi-Year Deal to Use Serve Robotics’ Sidewalk Bots for Deliveries

Adaptimmune Sells Tecelra and Late-Stage Cell Therapies to U.S. WorldMeds for $55M

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Never miss stories about

Acquisitions